1、 谢一娜,胡洪波,覃文办,等. 探讨胸水生化指标联合肿瘤标志物在肺癌患者恶性胸水鉴别诊断中的应用价值[J].中国医药指南,2019,17(5):105-106. 谢一娜,胡洪波,覃文办,等. 探讨胸水生化指标联合肿瘤标志物在肺癌患者恶性胸水鉴别诊断中的应用价值[J].中国医药指南,2019,17(5):105-106.
2、 黄芳,薛丽,宋琳岚,等. 胸水和血清 CEA、CA125、CYFRA21-1、NSE 和 Pro-GRP 联合检测对肺癌的诊断价值[J].现代肿瘤医学,2018,26(13):2054-2058. 黄芳,薛丽,宋琳岚,等. 胸水和血清 CEA、CA125、CYFRA21-1、NSE 和 Pro-GRP 联合检测对肺癌的诊断价值[J].现代肿瘤医学,2018,26(13):2054-2058.
3、 TURNER B M,CAGLE P T,SAINZ I M,et al. Napsin A,a new marker for lung adenocarnoma,is complementary and more sensitive and specific than thyroid transcription fator 1 in the differential diagnosis of primary pulmonary carcinoma:evalution of 1674 case by tissue microatty[J].Arch Pathol Lab Med,2012,136(2):163-171. TURNER B M,CAGLE P T,SAINZ I M,et al. Napsin A,a new marker for lung adenocarnoma,is complementary and more sensitive and specific than thyroid transcription fator 1 in the differential diagnosis of primary pulmonary carcinoma:evalution of 1674 case by tissue microatty[J].Arch Pathol Lab Med,2012,136(2):163-171.
4、 余清,吴宁,苏亚婷,等. TTF-1及Napsin A在肺腺癌胸水中的表达及临床意义 [J].临床肺科杂志,2019,24(4):618-621. 余清,吴宁,苏亚婷,等. TTF-1及Napsin A在肺腺癌胸水中的表达及临床意义 [J].临床肺科杂志,2019,24(4):618-621.
5、 徐晓艳,杜华,宝鲁日,等. 非小细胞肺癌活检标本中CK7、TTF-1、Napsin A、CK5/6及p63的表达及其意义[J].诊断病理学杂志,2015,22(11):688-691. 徐晓艳,杜华,宝鲁日,等. 非小细胞肺癌活检标本中CK7、TTF-1、Napsin A、CK5/6及p63的表达及其意义[J].诊断病理学杂志,2015,22(11):688-691.
6、 章文华,项晶晶,孙丽娟,等. 肺腺癌中TTF-1与Napsin A的病理诊断价值比较[J].临床与实验病理学杂志,2016,32(9):1028-1032. 章文华,项晶晶,孙丽娟,等. 肺腺癌中TTF-1与Napsin A的病理诊断价值比较[J].临床与实验病理学杂志,2016,32(9):1028-1032.
7、 YAMASHITA Y,NAGASAK A,NAIKI A,et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma[J]. Mod Pathol, 2015,28(1):111-117. YAMASHITA Y,NAGASAK A,NAIKI A,et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma[J]. Mod Pathol, 2015,28(1):111-117.
8、 BIN X, SAMUEL A, KANISHKA S,et al. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases [J]. Immunohistochem Mol Morphol, 2014,22(3):206-212. BIN X, SAMUEL A, KANISHKA S,et al. Diagnostic and prognostic role of immunohistochemical expression of napsin-A aspartic peptidase in clear cell and papillary renal cell carcinoma: a study including 233 primary and metastatic cases [J]. Immunohistochem Mol Morphol, 2014,22(3):206-212.
9、 刘标,周晓军. 非小细胞肺癌免疫组化标记物专家共识(2014) [J].临床与实验病理学杂志,2015,31(9):481-487. 刘标,周晓军. 非小细胞肺癌免疫组化标记物专家共识(2014) [J].临床与实验病理学杂志,2015,31(9):481-487.
10、 张爱丽,孙宇,徐少艳,等. 免疫组化在肺小活栓中对鳞状细胞癌和腺癌的鉴别诊断意义[J].诊断病理学杂志,2016,23(1):70-72. 张爱丽,孙宇,徐少艳,等. 免疫组化在肺小活栓中对鳞状细胞癌和腺癌的鉴别诊断意义[J].诊断病理学杂志,2016,23(1):70-72.
11、 SKOOG L,TANI E. Immunohistochemistry:an indispensable technique in rouin ecytology[J].Cytopathology,2011,22(4):215-229. SKOOG L,TANI E. Immunohistochemistry:an indispensable technique in rouin ecytology[J].Cytopathology,2011,22(4):215-229.
12、 ENSMAI F,NEMATIXADEH F,IRXANLO G. Accuracy of immunohistochemistry in evaluation of malignant pleural effusionsand peritoneal effusions[J].Pol J Pathol,2011,62(2):95-100. ENSMAI F,NEMATIXADEH F,IRXANLO G. Accuracy of immunohistochemistry in evaluation of malignant pleural effusionsand peritoneal effusions[J].Pol J Pathol,2011,62(2):95-100.
13、 SHIVAKUMARMY U,ARAKERI S U,KARIGOWDAR M H,et al. Diagnostic utility of the cell block method versus the conventional smear study in pleuralfluid cytology[J].J Cytol,2012,29(1):11-15. SHIVAKUMARMY U,ARAKERI S U,KARIGOWDAR M H,et al. Diagnostic utility of the cell block method versus the conventional smear study in pleuralfluid cytology[J].J Cytol,2012,29(1):11-15.
14、 吴秉铨,刘彦仿. 免疫组织化学病理诊断[M]. 北京:北京科学技术出版,2007:221-223. 吴秉铨,刘彦仿. 免疫组织化学病理诊断[M]. 北京:北京科学技术出版,2007:221-223.
15、 刘芳,何欣,李晓琴. 免疫组化标记物在鉴别浆膜腔积液恶性肿瘤细胞中的应用价值[J].临床与实验病理学杂志,2018,34(2):201-204. 刘芳,何欣,李晓琴. 免疫组化标记物在鉴别浆膜腔积液恶性肿瘤细胞中的应用价值[J].临床与实验病理学杂志,2018,34(2):201-204.
16、 徐小艳,刘红伟,姜黄,等. 联合检测细胞蜡块中的napsinA和甲状腺转录因子-1有助于肺腺癌胸水的诊断[J].南方医科大学学报,2015,35(11):1610-1613. 徐小艳,刘红伟,姜黄,等. 联合检测细胞蜡块中的napsinA和甲状腺转录因子-1有助于肺腺癌胸水的诊断[J].南方医科大学学报,2015,35(11):1610-1613.
17、 FELLER-KOPAMAN D J,REDDY C B,DECAMP M M,et al. Management of malignant pleural effusions. an official AST/STS/STR clinical practice guideline[J].Am J Respir Crit Care Med,2018,198(7):839. FELLER-KOPAMAN D J,REDDY C B,DECAMP M M,et al. Management of malignant pleural effusions. an official AST/STS/STR clinical practice guideline[J].Am J Respir Crit Care Med,2018,198(7):839.
